Literature DB >> 8597747

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.

M T Silva, P M Watts, P Jenner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8597747      PMCID： PMC2350542          DOI： 10.1136/bmj.312.7032.703

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  2 in total

1.  Selegiline in Parkinson's disease.

Authors:  D B Calne
Journal:  BMJ       Date:  1995-12-16

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154
  2 in total
  2 in total

1.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

2.  Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Authors:  Y Mizuno; T Kondo
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.